European Respiratory Society International Congress, Madrid 29 September 2019 Dr Steve Pawsey, CMO at NeRRe Therapeutics presents a poster at [...]
Initially targeting Refractory or Unexplained Chronic Cough, a common, long-lasting and debilitating condition, experienced by millions of people worldwide, for which there is no approved treatment.
A unique approach
NeRRe Therapeutics is a UK based clinical stage company progressing a unique portfolio of three neurokinin-1 antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions, caused by neural hypersensitivity related to Substance P/ NK-1 receptor system dysfunction. The lead NK-1RA compound orvepitant has just completed a multinational Phase 2b dose range finding study “VOLCANO-2”, in patients suffering from Refractory or Unexplained Chronic Cough with positive results.
For general, media or partnership enquiries, get in touch with us: